AMAG Acquires Lumara Health for Over $1 Billion
AMAG Pharmaceuticals announced the acquisition of women?s health brand, Lumara Health, for $675 million, with an additional contingency of up to $350 million.
AMAG Pharmaceuticals announced on Sept. 29, 2014 that is has entered an agreement to acquire Lumara Health for $675 million, offering an additional $350 million based on milestone achievements.
Lumara Health specializes in women’s health pharmaceuticals throughout the stages of a woman’s life, with a focus on maternal health. Within the agreement, AMAG acquires Makena (hydroxyprogesterone caproate injection), Lumara’s FDA-approved drug to reduce the risk of preterm birth in women who have already had a premature baby and are currently pregnant.
"This is a truly transformative transaction that will propel AMAG into a profitable, high-growth multi-product specialty pharmaceutical company positioned for what we expect to be continued revenue and bottom-line growth, further business diversification, and shareholder value creation,” said William Heiden, president and CEO of AMAG.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
